Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
Activist investors last year called for GSK to find an outright buyer for the consumer division, and may now get their wish.
Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.
After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.
CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.